For type 2 diabetes mellitus. ANDA 206955, held by Macleods Pharms. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 206955 (Metformin Hydrochloride), held by Macleods Pharms, was first approved by FDA on Dec 7, 2016, with 5 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 7, 2016 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 36Labeling · Standard review | Approved | None posted |
| Jun 7, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 17, 2019 | Supplement 12Manufacturing · Standard review | Approved | None posted |
| Dec 7, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters